PMID- 34761684
OWN - NLM
STAT- MEDLINE
DCOM- 20220812
LR  - 20231124
IS  - 1724-6016 (Electronic)
IS  - 1120-6721 (Print)
IS  - 1120-6721 (Linking)
VI  - 32
IP  - 5
DP  - 2022 Sep
TI  - Ocular adverse events following intravitreal brolucizumab for neovascular 
      age-related macular degeneration at a single tertiary care center.
PG  - 2747-2751
LID - 10.1177/11206721211059332 [doi]
AB  - PURPOSE: To determine the incidence of ocular adverse effects (AEs) following 
      brolucizumab injection for neovascular age-related macular degeneration at a 
      tertiary academic institution. DESIGN: Retrospective, single center cohort study. 
      PARTICIPANTS: All patients who received an intravitreal injection of brolucizumab 
      6 mg for neovascular age-related macular degeneration between October 7, 2019 and 
      July 31, 2020. METHODS: Medical records of all patients who received brolucizumab 
      6 mg during the aforementioned time period were carefully reviewed and all ocular 
      adverse effects after injection were charted. MAIN OUTCOME MEASURES: Incidence of 
      post-injection ocular AEs, including intraocular inflammation (IOI), and time to 
      development of AEs after injection. RESULTS: A total of 77 patients received 
      brolucizumab 6 mg for a total of 115 administrations during the study period. 
      There were 4 AEs (3.5%), including three cases of IOI (2.6%), one central retinal 
      artery occlusion, and one retinal detachment. Two men and two women were 
      affected. CONCLUSION: Ocular AEs, including those leading to severe vision loss, 
      may develop after intravitreal brolucizumab 6 mg. A careful discussion of 
      benefits and risks to brolucizumab should be conducted with all patients. PRECIS: 
      In this first case series of ocular adverse effects after brolucizumab 6 mg 
      injection at a single tertiary care center, the incidence of ocular adverse 
      effects was 3.5%, including a 2.6% incidence of intraocular inflammation.
FAU - Nguyen, Huy V
AU  - Nguyen HV
AD  - Byers Eye Institute at Stanford, 10624Stanford University School of Medicine, 
      Palo Alto, CA, USA.
FAU - Li, Angela S
AU  - Li AS
AUID- ORCID: 0000-0002-0397-2193
AD  - Byers Eye Institute at Stanford, 10624Stanford University School of Medicine, 
      Palo Alto, CA, USA.
FAU - Silva, Amila R
AU  - Silva AR
AD  - Byers Eye Institute at Stanford, 10624Stanford University School of Medicine, 
      Palo Alto, CA, USA.
FAU - Leng, Theodore
AU  - Leng T
AUID- ORCID: 0000-0002-8461-3562
AD  - Byers Eye Institute at Stanford, 10624Stanford University School of Medicine, 
      Palo Alto, CA, USA.
LA  - eng
GR  - P30 EY026877/EY/NEI NIH HHS/United States
PT  - Journal Article
DEP - 20211111
PL  - United States
TA  - Eur J Ophthalmol
JT  - European journal of ophthalmology
JID - 9110772
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - XSZ53G39H5 (brolucizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/adverse effects
MH  - Antibodies, Monoclonal, Humanized
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Inflammation
MH  - Intravitreal Injections
MH  - *Macular Degeneration/drug therapy
MH  - Male
MH  - Retrospective Studies
MH  - Tertiary Care Centers
MH  - *Uveitis/drug therapy
MH  - Visual Acuity
PMC - PMC10666666
MID - NIHMS1945499
OTO - NOTNLM
OT  - Age-related macular degeneration
OT  - anterior uveitis
OT  - arterial occlusive disease
OT  - choroidal/retinal inflammation
OT  - retina - medical therapies
COIS- Declaration of conflicting interests The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2021/11/12 06:00
MHDA- 2022/08/13 06:00
PMCR- 2023/11/23
CRDT- 2021/11/11 08:36
PHST- 2021/11/12 06:00 [pubmed]
PHST- 2022/08/13 06:00 [medline]
PHST- 2021/11/11 08:36 [entrez]
PHST- 2023/11/23 00:00 [pmc-release]
AID - 10.1177/11206721211059332 [doi]
PST - ppublish
SO  - Eur J Ophthalmol. 2022 Sep;32(5):2747-2751. doi: 10.1177/11206721211059332. Epub 
      2021 Nov 11.